GLPwatch

Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

NCT04998136 · Completed

Last updated 2026-05-28

This clinical trial is testing how well the medication semaglutide reduces body weight in adults from Thailand and South Korea who are living with obesity.

Status Completed The study has finished.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 150 people
Who can join Ages 18+ · all sexes
Timeline Started 2022-08 · est. completion 2023-11
Where 16 sites · South Korea, Thailand

What this study is testing ClinicalTrials.gov NCT04998136 ↗

Description as written by the study sponsor.

This study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study. The study compares the weight loss in people who get semaglutide to the weight loss in people who get placebo. Placebo is a "dummy" medicine that looks like the study medicine, but has no effect on the body. Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. Participants will also have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. The study will last for about a year (50 weeks). Participants will have 10 clinic visits and 8 phone calls. At 6 of the clinic visits participants will have blood samples taken. Participants cannot take part if participants have or have had diabetes. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

Treatments tested

Main thing measuredChange in Body Weight (%) : In-trial Observation Period
SponsorNovo Nordisk A/S
Conditions studiedObesity
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04998136 ↗